Notch is building best-in-class T cell therapies.
We’ve developed a UNiversal T cell derived from induced pluripotent stem cells (iPSCs). Our new UNi-T Cell is an off-the-shelf solution that solves key challenges in adoptive cell therapy.
Current CAR-T therapies harvest and genetically modify T cells, patient by patient, and have been transforming the treatment of blood cancers for several years. Compared to small molecules or biologics, a T cell’s behavior makes it an ideal therapeutic – it can expand in response to disease targets, actively penetrate tissues, and persist to monitor for future disease recurrence. However, when approximately six percent of patients in approved indications receive this kind of treatment today-and when there is enormous potential for CAR-T therapies to treat so many more diseases-there’s a problem. And it comes down to commercial potential and cost.
Notch’s iPSC-derived T cell approach, the UNi-T Cell, eliminates the need for the costly and variable modification and manufacture of patient- or donor-sourced cells and allows us to develop persistent and potent cell therapies with patient experience and access in mind. This means our products will be able to provide a uniform, cost effective, and accessible CAR-T option to many more patients.
For information about open positions:
Careers >
With offices in Vancouver, Seattle and Toronto, Notch Therapeutics operates on the traditional, ancestral and unceded territories of the Musqueam, Squamish and Tsleil-Waututh Nations; the ancestral land of the Duwamish, Suquamish, Stillaguamish, and Muckleshoot people; and the Treaty Lands and Territory of the Mississaugas of the Credit First Nation as well as the traditional territory of the Huron-Wendat and Haudenosaunee peoples. We thank these First Peoples who continue to live on these lands and care for them, and whose relationship to these lands existed long before the founding of Canada or the United States of America.